Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcareNovo Nordisk will integrate OpenAI’s most advanced AI capabilities globally from drug discovery to commercial operations, empowering talent to move faster, work smarter, and deliver life-changing outcomes for patientsThe partnership has been structured with strict data governance and human oversight to ensure ethical and compliant use
Bagsværd, Denmark, 14 April 2026 – Novo Nordisk today announced a strategic partnership with OpenAI that will place Novo Nordisk at the forefront of AI transformation in healthcare and help the company bring new and better treatment options to patients faster.
The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient. It has been structured with strict data protection, governance and human oversight to ensure ethical and compliant use.
“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” said Mike Doustdar, president and CEO of Novo Nordisk. “Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.”
OpenAI will assist Novo Nordisk in upskilling the company’s global workforce and enhancing AI literacy. The partnership will also apply OpenAI’s capabilities to improve efficiency in manufacturing, supply chain and distribution and corporate operations. Pilot programmes will launch across research & development, manufacturing and commercial operations, with
